South and Central America Non-Alcoholic Steatohepatitis Market Forecast to 2028

Report Code : BMIRE00025408 | Region : LAMEA | Industry : Pharmaceuticals | Published Date : 18/Jul/2022
South and Central America Non-Alcoholic Steatohepatitis Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product (Vitamin E and Pioglitazone, Ocaliva, Elafibranor, Selonsertib, Cenicriviroc, and Others), Application (Treatment and Diagnosis), and Sales Channel (Hospital Pharmacy, Online Provider, and Retail Pharmacy)

The South & Central America Non-Alcoholic Steatohepatitis market is expected to reach US$ 303.88 million by 2028 from US$ 44.76 million in 2021. The market is estimated to grow at a CAGR of 31.5% from 2021 to 2028.

There is a growing trend in collaborations among pharmaceutical companies to broaden combination therapies. Monotherapy is probable to put up modest or equivocal data and, therefore, will now no longer be a powerful therapy. This is because of NASH’s complex pathophysiology (oxidant stress, inflammation activation, fibrogenesis, microbiome, increased intestinal perSAMbility, and immune cell mechanisms) that affect the heterogeneity of phenotypes. Hence, the improvement of a single therapy for NASH appears complex and unlikely, regardless of the plethora of later-stage trials because of the report. Several drugs are presently being tested with Farnesoid X receptor (FXR) agonists. For instance, the combinations of Tropifexor/CVC (Allergan and Novartis), Semaglutide/Cilofexor/Firsocostat (Novo Nordisk and Gilead), and Selonsertib/Cilofexor/Firsocostat (Gilead, now discontinued). Novartis is recruiting 380 NASH patients with stage 2 or 3 Clinical Research Network (CRN) fibrosis in other drug combination trials to evaluate Licogliflozin, an SGLT1/2 inhibitor, and Tropifexor in combination or alone with a Phase 2 ELIVATE clinical trial, that is anticipated to finish by 2023. Metacrine Inc. compares other FXR agonists, MET409, in a Phase 2a combination trial (ClinicalTrials.gov NCT04702490) with an SGLT2 inhibitor-Empagliflozin (Jardiance) in patients with NASH and T2D. Pfizer Inc has taken into consideration combination therapies as properly and assessed the impact of PF-06865571 (a DGAT2 inhibitor) and PF-05221304 (an ACC inhibitor) on whole-liver fats in subjects with NAFLD in comparison to placebo in a short, 6-week Phase 2a clinical trial (ClinicalTrials.gov NCT03776175). Both drugs alone and in combination considerably decreased liver fats compared to placebo; however, there is no evidence of additivity (or synergy) with no huge differences among each monotherapy compared with the combination therapy. By the end of 2020, Pfizer conveyed that PF-05221304 was no longer in its pipeline and was discontinued as a monotherapy. Furthermore, Pfizer recently included a Phase 1 clinical trial of their pipeline to evaluate PF-06882961 (Danuglipron), a GLP-1R agonist in combination with PF-06865571, for the treatment of NASH. Thus, growing clinical trials involving combination studies of drugs are expected to emerge as a trend in the forecast period. The South & Central America non-alcoholic steatohepatitis market is expected to grow at a good CAGR during the forecast period.

South & Central America Non-Alcoholic Steatohepatitis Revenue and Forecast to 2028 (US$ Million)

South & Central America Non-Alcoholic Steatohepatitis Market Segmentation

The South & Central America Non-Alcoholic Steatohepatitis market segmented into product, application, sales channel and country. Based on product type the South & Central America Non-Alcoholic Steatohepatitis market is segmented into vitamin e and pioglitazone, ocaliva, elafibranor, selonsertib,cenicriviroc and others. The selonsertib & cenicriviroc segment is expected to be the fastest growing segment over the forecaste period.Based on application the South & Central America Non-Alcoholic Steatohepatitis market segmented into treatment and diagnosis. The treatment segment is dominated South & Central America Non-Alcoholic Steatohepatitis market in 2020. Based on sales channel, the South & Central America Non-Alcoholic Steatohepatitis market segmented into hospital pharmacy, online provider, and retail pharmacy. The retail pharmacy segment is dominated South & Central America Non-Alcoholic Steatohepatitis market in 2020. Based on country, the South & Central America non-alcoholic steatohepatitis market is segmented into Brazil, Argentina, and the rest of South & Central America. The Brazil dominated the South & Central America non-alcoholic steatohepatitis market in 2020.

Cadila Pharmaceutical, Intercept Pharmaceutical, Novartis AG, Galmed Pharmaceutical, GENFIT, Siemens Healthineers AG, and Laboratory Corporation of America Holdings are among the leading companies in the South & Central America non-alcoholic steatohepatitis market.

The List of Companies - South and Central America Non-Alcoholic Steatohepatitis Market

● Cadila Pharmaceutical.

● Intercept Pharmaceutical.

● Novartis AG.

● Galmed Pharmaceutical.

● GENFIT.

● Siemens Healthineers AG.

● Laboratory Corporation of America Holdings.

TABLE OF CONTENTS

1. Introduction

1.1 Scope of the Study

1.2 The Insight Partners Research Report Guidance

1.3 Market Segmentation

1.3.1 SAM Non-Alcoholic Steatohepatitis Market – By Product

1.3.2 SAM Non-Alcoholic Steatohepatitis Market – By Application

1.3.3 SAM Non-Alcoholic Steatohepatitis Market – By Sales Channel

1.3.4 SAM Non-Alcoholic Steatohepatitis Market – By Country

2. Key Takeaways

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. SAM Non-Alcoholic Steatohepatitis Market – Market Landscape

4.1 Overview

4.2 PEST Analysis

4.2.1 South And Central America PEST Analysis

4.3 Experts Opinion

5. SAM Non-alcoholic steatohepatitis (NASH) Market – Key Market Dynamics

5.1 Market Drivers

5.1.1 Rising Prevalence of NASH

5.1.2 Increasing Initiatives for the Awareness of NASH

5.2 Market Restraints

5.2.1 Lack of Established Guidelines in the Diagnosis and Management of NASH

5.2.2 Withdrawal of Drugs from Seeking Marketing Authorization for NASH

5.3 Market Opportunities

5.3.1 Growing Opportunities in Developing Nations

5.3.2 High Competition among Market Players to Manufacture the First Marketed NASH Drug Creates Global Sales Opportunity

5.4 Future Trends

5.4.1 Growing Clinical Trials Involving Combination Studies of Drugs

5.5 Impact Analysis

6. Non-alcoholic steatohepatitis (NASH) Market– SAM Analysis

6.1 SAM Non-Alcoholic Steatohepatitis Market Revenue Forecast and Analysis

7. SAM Non-alcoholic steatohepatitis (NASH) Market Revenue and Forecasts To 2028– by Product

7.1 Overview

7.2 Product Market Revenue and Forecast Analysis (US$ Mn)

7.3 Vitamin E and Pioglitazone

7.3.1 Overview

7.3.2 Vitamin E and Pioglitazone Revenue and Forecast to 2028 (US$ Mn)

7.4 Ocaliva

7.4.1 Overview

7.4.2 Ocaliva Revenue and Forecast to 2028 (US$ Mn)

7.5 Elafibranor

7.5.1 Overview

7.5.2 Elafibranor Revenue and Forecast to 2028 (US$ Mn)

7.6 Selonsertib & Cenicriviroc

7.6.1 Overview

7.6.2 Selonsertib Revenue and Forecast to 2028 (US$ Mn)

7.7 Others

7.7.1 Overview

7.7.2 Others Revenue and Forecast to 2028 (US$ Mn)

8. SAM Non-Alcoholic Steatohepatitis (NASH) Market Analysis and Forecast to 2028 – by Application

8.1 Overview

8.2 Application Market Revenue and Forecast Analysis (US$ Mn)

8.3 Treatment

8.3.1 Overview

8.3.2 Treatment Market Revenue and Forecast to 2028 (US$ Mn)

8.4 Diagnosis

8.4.1 Overview

8.4.2 Diagnosis Market Revenue and Forecast to 2028 (US$ Mn)

9. SAM Non-Alcoholic Steatohepatitis (NASH) Market Analysis and Forecast to 2028 – by Sales Channel

9.1 Overview

9.2 Sales Channel Market Revenue and Forecast Analysis (US$ Mn)

9.3 Hospital Pharmacy

9.3.1 Overview

9.3.2 Hospital Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)

9.4 Retail Pharmacy

9.4.1 Overview

9.4.2 Retail Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)

9.5 Online Provider

9.5.1 Overview

9.5.2 Online Provider Market Revenue and Forecast to 2028 (US$ Mn)

10. SAM Non-alcoholic steatohepatitis (NASH) Market Revenue and Forecasts to 2028 – Country Analysis

10.1 South and Central America Non-Alcoholic Steatohepatitis Market Revenue and Forecast To 2028

10.1.1 Overview

10.1.3 South and Central America: Non-Alcoholic Steatohepatitis Market, by Country, 2021 & 2028 (%)

10.1.3.1 Brazil: Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (USD Million)

10.1.3.1.1 Brazil: Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (USD Million)

10.1.3.1.2 Brazil: Non-Alcoholic Steatohepatitis Market , by Product, 2019–2028 (USD Million)

10.1.3.1.3 Brazil: Non-Alcoholic Steatohepatitis Market, by Application, 2019–2028 (USD Million)

10.1.3.1.4 Brazil: Non-Alcoholic Steatohepatitis Market, by Sales Channel, 2019–2028 (USD Million)

10.1.3.2 Argentina: Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (USD Million)

10.1.3.2.1 Argentina: Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (USD Million)

10.1.3.2.2 Argentina: Non-Alcoholic Steatohepatitis Market , by Product, 2019–2028 (USD Million)

10.1.3.2.3 Argentina: Non-Alcoholic Steatohepatitis Market , by Application, 2019–2028 (USD Million)

10.1.3.2.4 Argentina: Non-Alcoholic Steatohepatitis Market, by Sales Channel, 2019–2028 (USD Million)

10.1.3.3 Rest of South and Central America: Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (USD Million)

10.1.3.3.1 Rest of South and Central America: Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (USD Million)

10.1.3.3.2 Rest of South and Central America: Non-Alcoholic Steatohepatitis Market , by Product, 2019–2028 (USD Million)

10.1.3.3.3 Rest of South and Central America: Non-Alcoholic Steatohepatitis Market , by Application, 2019–2028 (USD Million)

10.1.3.3.4 Rest of South and Central America: Non-Alcoholic Steatohepatitis Market , by Sales Channel, 2019–2028 (USD Million)

11. Industry Landscape

11.1 Overview

11.2 Organic Developments

11.2.1 Overview

11.3 Inorganic Developments

11.3.1 Overview

12. Company Profiles

12.1 Cadila Pharmaceuticals Ltd.

12.1.1 Key Facts

12.1.2 Business Description

12.1.3 Products and Services

12.1.4 Financial Overview

12.1.5 SWOT Analysis

12.1.6 Key Developments

12.2 Intercept Pharmaceuticals, Inc

12.2.1 Key Facts

12.2.2 Business Description

12.2.3 Products and Services

12.2.4 Financial Overview

12.2.5 SWOT Analysis

12.2.6 Key Developments

12.3 Novartis AG

12.3.1 Key Facts

12.3.2 Business Description

12.3.3 Products and Services

12.3.4 Financial Overview

12.3.5 SWOT Analysis

12.3.6 Key Developments

12.4 Galmed Pharmaceuticals.

12.4.1 Key Facts

12.4.2 Business Description

12.4.3 Products and Services

12.4.4 Financial Overview

12.4.5 SWOT Analysis

12.4.6 Key Developments

12.5 GENFIT.

12.5.1 Key Facts

12.5.2 Business Description

12.5.3 Products and Services

12.5.4 Financial Overview

12.5.5 SWOT Analysis

12.5.6 Key Developments

12.6 Siemens Healthineers AG

12.6.1 Key Facts

12.6.2 Business Description

12.6.3 Products and Services

12.6.4 Financial Overview

12.6.5 SWOT Analysis

12.6.6 Key Developments

12.7 Laboratory Corporation of America Holdings

12.7.1 Key Facts

12.7.2 Business Description

12.7.3 Products and Services

12.7.4 Financial Overview

12.7.5 SWOT Analysis

12.7.6 Key Developments

13. Appendix

13.1 About The Insight Partners

13.2 Glossary of Terms

LIST OF TABLES.

Table 1. Brazil: Non-Alcoholic Steatohepatitis Market , by Product – Revenue and Forecast to 2028 (USD Million)

Table 2. Brazil: Non-Alcoholic Steatohepatitis Market, by Application– Revenue and Forecast to 2028 (USD Million)

Table 3. Brazil: Non-Alcoholic Steatohepatitis Market, by Sales Channel– Revenue and Forecast to 2028 (USD Million)

Table 4. Argentina: Non-Alcoholic Steatohepatitis Market , by Product – Revenue and Forecast to 2028 (USD Million)

Table 5. Argentina: Non-Alcoholic Steatohepatitis Market , by Application– Revenue and Forecast to 2028 (USD Million)

Table 6. Argentina: Non-Alcoholic Steatohepatitis Market , by Sales Channel– Revenue and Forecast to 2028 (USD Million)

Table 7. Rest of South and Central America: Non-Alcoholic Steatohepatitis Market , by Product – Revenue and Forecast to 2028 (USD Million)

Table 8. Rest of South and Central America: Non-Alcoholic Steatohepatitis Market , by Application– Revenue and Forecast to 2028 (USD Million)

Table 9. Rest of South and Central America: Non-Alcoholic Steatohepatitis Market , by Sales Channel– Revenue and Forecast to 2028 (USD Million)

Table 10.   Organic Developments Done By Companies

Table 11.   Inorganic Developments Done By Companies

Table 12.   Glossary of Terms

The List of Companies - South and Central America Non-Alcoholic Steatohepatitis Market

● Cadila Pharmaceutical.

● Intercept Pharmaceutical.

● Novartis AG.

● Galmed Pharmaceutical.

● GENFIT.

● Siemens Healthineers AG.

● Laboratory Corporation of America Holdings.

Reason To Buy

● Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the South & Central America Non-Alcoholic Steatohepatitis market forecast.

● Highlights key business priorities in order to assist companies to realign their business strategies

● The key findings and recommendations highlight crucial progressive industry trends in South & Central America Non-Alcoholic Steatohepatitis market forecast, thereby allowing players across the value chain to develop effective long-term strategies

● Develop/modify business expansion plans by using substantial growth offering developed and emerging markets

● Scrutinize in-depth South & Central America market trends and outlook coupled with the factors driving the non-alcoholic steatohepatitis, as well as those hindering it.

● Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.

AVAILABLE CUSTOMIZATION RESEARCH METHODOLOGY REQUEST FOR TOC FREE SAMPLE REPORT
CHOOSE LICENCE TYPE
(South and Central America Non-Alcoholic Steatohepatitis Market Forecast to 2028 )
  • Single User Price $3,000$2,400
  • Site Price $4,000$3,200
  • Enterprise Price $5,000$4,000
Buy Now Add to Cart
REQUEST FOR TOC
SPEAK TO ANALYST
FREE SAMPLE
REPORT
INQUIRE BEFORE
BUYING
TOP
Quick Enquiry